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Obesity is a chronic disease, whose incidence is alarmingly growing. It is associated with metabolic abnormalities and cardiovascu-
lar complications. These complications are clustered in the metabolic syndrome (MetS) leading to high cardiovascular morbidity
and mortality. Obesity predisposes to diabetic nephropathy, hypertensive nephrosclerosis, and focal and segmental glomerular
sclerosis and represents an independent risk factor for the development and progression of chronic kidney disease (CKD).
Albuminuriaisamajorriskfactorforcardiovasculardiseases(CVDs).Microalbuminuriahasbeendescribedasearlymanifestation
of MetS-associated kidney damage and diabetic nephropathy. Obesity and MetS aﬀect renal physiology and metabolism through
mechanisms which include altered levels of adipokines such as leptin and adiponectin, oxidative stress, and inﬂammation.
Secretory products of adipose tissue also deeply and negatively inﬂuence endothelial function. A better understanding of these
interactions will help in designing more eﬀective treatments aimed to protect both renal and cardiovascular systems.
1.Introduction
The prevalence of obesity, among both adults and children,
has worldwide increased over the past two decades; a phe-
nomenon which is predominantly attributed to the change
indietaryhabitsandlifestylemodiﬁcations [1,2].Itisclearly
knows that central obesity is an independent risk factor for
CVD and is associated with Mets. Insulin resistance (IR) is a
key feature of the Mets and consists in a decreased sensitivity
or responsiveness of peripheral tissues to the metabolic
action of insulin [3]. IR as well as all components of the Mets
are associated with altered functions of endothelium which
lead to CVD [4]. Hyperlipemia and coronary artery disease
are also consequences of obesity which through a cascade
of various reactions lead to kidney dysfunction. Moreover,
obesity-induced sleep apnoea activates sympathetic nervous
system increasing the tone of the glomerular eﬀerent arteri-
oles and the secretion of renin and angiotensin [5]. In the
last decade, obesity has been suggested as a risk factor for
chronic kidney disease, decline of renal function, and low-
gradealbuminuria,butconﬂictingresultshavebeenreported
[6–10]. Yet obesity, per se, even in the absence of the above-
mentioned medical complications alters renal physiology
and metabolism. In this paper, we will examine the role
of adipose tissue-secreted factors and the mechanisms of
obesity-induced renal and vascular injury leading to chronic
kidney and cardiovascular diseases.
2. Epidemiology of Mets, CKD, andCVD
CVD accounts for premature death in about 50% of dialysis
patients [11]. As early as 1974, Lindner et al. demonstrated
that dialysis patients have a higher prevalence of CVD com-
pared to the general population [12]. The strong association
between mild CKD and CVD has been shown, and recently
Henry et al. reported that mild to moderate CKD is strongly2 Cardiology Research and Practice
associated with an increase in cardiovascular mortality [13,
14].
Ninomiya et al. recently examined the relationship
between Mets and CKD [15]. They performed a slope
analysis of the association between the glomerular ﬁltration
rate (GFR) slope and Mets by using a multiple regression
model. GFR decreased signiﬁcantly faster in patients with 4
or more Mets components compared with those who had 1
or no components. Moreover the mean of the GFR slope was
signiﬁcantly lowerin subjectswith3 Metscomponentsin the
60 year and over group. In a large cohort of the NHANES
III study with baseline normal renal function, Chen et al.
examined the risk of developing CVD following patients for
more than 20 years [16].
Interestingly, there also was a 2-fold increase in the risk
of microalbuminuria that correlates with the number of
components of Mets. Moreover, even low-grade albuminuria
below the conventional cut-oﬀ point for albuminuria was
associatedwithincreasedprevalenceofCKD[17].Datafrom
the MESA [18] and LIFE studies [19] clearly demonstrated
that albuminuria is one of the strongest risk factors for
cardiovascular disease (CVD).
3 .A d ipo seT iss ueA sanA c ti v eEnd oc rineO rgan
There are multiple changes in adipose tissue in obesity inc-
luding increase in numbers and size of adipocytes, inﬁltra-
tion of adipose by mononuclear cells, rarefaction of blood
vessels, increases in adipocyte turnover rate, diﬀerentiation,
and apoptosis [20]. The capillary diﬀusion capacity is
reduced in patients with obesity and, in contrast with the
response of lean subject, the adipose blood ﬂow does not
increase in response to food in obese patients [21]. Since the
discoveryofleptinasanadipocyte-derivedsatietyfactor,adi-
pose tissue is increasingly being considered as an endocrine
organ. Adipose tissue secretes into the circulation a number
of proteins and nonprotein factors that regulate glucose and
lipid metabolism throughout the body. Among these bioac-
tive adipokines, only adiponectin (ADN), leptin, adipsin,
and visfatin are almost synthesized exclusively by adipocytes.
In obese patients, the production of ADN is reduced [22–
24]. ADN is a 30kDa protein present as oligomers in the
blood stream and has insulin-sensitizing, antiatherogenicity,
and anti-inﬂammatory properties. Reduction of ADN levels
is a consistent feature among obese patients who have
evidence of IR and often develop diabetes mellitus. ADN
plasma levels also negatively correlate with coronary artery
disease and dyslipidemia in both mice and humans [25–28].
Overexpression or AND administration reduces oxidative
stress, inﬂammation, IR, and vascular damage. Becker et
al. found that low ADN levels in mild to moderate kidney
disease were correlated with cardiovascular events [29].
The potential link between ADN levels and low-grade
albuminuria was ﬁrst observed in a clinical study where
essential hypertensive patients had a negative correlation
between ADN levels and low-grade albuminuria [30]. Later
on, similar results were also obtained in obese patients from
diﬀerent ethnic groups [31, 32]. Despite some controversial
observations [33, 34], clinical data strongly suggest the
potential causative role of ADN in the development of
albuminuria in obese patients. An important contribution in
understanding the potential link between obesity and kidney
damage comes from the work by Sharma [32]. In a recent
study, he showed that ADN knockout mice had baseline
increased albuminuria (twice normal values) with podocyte
foot process eﬀacement. Morphologically, the endothelium
appearedtobenormalunderelectronmicroscopy.Podocytes
expressed the AdipoR1 receptor and ADN regulated an
isoform of NAPDH oxidase through the AMPK pathway
[32]. When treating ADN knockout mice with ADN, pro-
teinuria was reversed and foot processes were normalized.
In mice, Sharma et al. [32] also demonstrated that ADN
deﬁciency was a susceptibility factor for early diabetic kidney
disease. Consequently, the podocyte may play an important
role in determining albuminuria associated with obesity
[35]. The role of endothelial dysfunction may be important
for albuminuria as well. At the present time, no data are
availabletodocumentthepresenceofglomerularendothelial
dysfunction in the presence of microalbuminuria. On the
otherhand,ithasbeenestablishedthatpodocytedysfunction
contributes to endothelial dysfunction [36, 37].
The increase of visceral fat promotes synthesis of proin-
ﬂammatory adipokines which cause tissue-speciﬁc increase
in reactive oxygen species derived from NADPH oxidase.
Adipose tissue oxidative stress results in the development of
systemic oxidative stress and inﬂammation, which further
lead to the development of metabolic abnormalities. Leptin,
a 167 amino acid polypeptide, is expressed mainly by
adipocytes; leptin concentration positively correlates with
adiposity [38], and hyperleptinemia is an independent risk
factor for coronary artery disease [39] and a strong predictor
of acute myocardial infarction [40]. Additionally, leptin has
been implicated in many atherogenic processes, including
platelet aggregation and thrombosis [41–43]; production of
inﬂammatory cytokines, for example, TNF-α, IL-6, and IL-
12 [44]; calciﬁcation of vascular smooth muscle cells [45].
Interestingly, recent reports have demonstrated that leptin
possesses cytokine-like properties and that elevated plasma
leptin levels occur concomitantly with elevated IL-6 and C-
reactive protein in human obesity, the Mets, and noninsulin-
dependent diabetes mellitus [46–48]. Animal testing showed
that leptin induces proliferation of glomerular endothelial
cells, enhances glomerular TGF-β1 beta expression, and
increases collagen type IV mRNA production [49]. These
factors result in focal glomerulosclerosis, glomerular and
mesangialglucoseuptake,andproteinuria[49].Additionally,
leptin is also associated with adrenergic activation, increased
blood pressure and tachicardia, contributing to obesity-
related hypertension and kidney damage [50–53].
In recent years, a great deal of attention has been focused
on the orexigenic peptide ghrelin which is predominantly
secreted by the stomach [54, 55]. Patients with obesity-
related Mets have reduced ghrelin circulating levels. Ghrelin
has important vascular actions; it acutely stimulates produc-
tion of NO in vascular endothelium through a PI3-kinase-
dependent mechanism involving phosphorylation of Akt
which directly phosphorylates and activates eNOS leading
to increased production of NO [56]. This signaling pathwayCardiology Research and Practice 3
is similar to that used by insulin to promote increased
production of NO in vascular endothelium. Moreover, we
have demonstrated that intra-arterial ghrelin administration
acutelyimprovesendothelialdysfunctionbyincreasingnitric
oxide (NO) and decreases ET-1-dependent vasoconstriction,
thereby restoring the physiological balance between these
opposing vascular mediators in patients with central obesity
[57, 58].
Thus, therapeutic interventions including weight loss,
exercise, or pharmacological therapies that increase plasma
ghrelin levels could to contribute to this strategies by
mimicking and/or augmenting beneﬁcial eﬀects of increased
insulin sensitivity.
Dysregulation of adipokines synthesis and release into
the blood stream occur in obese patients and play a critical
role in promoting IR [59–61]; diabetes and dyslipidemia are
characterized by low adiponectin levels and elevated levels of
inﬂammatory adipokines such as TNF-alpha (TNF-α)[ 62].
Adipose tissue also expresses a local renin-angiotensin
system (RAS). Adipocytes express RAS receptors and syn-
thesizeandsecreteangiotensinogenandangiotensinpeptides
[63]. RAS is a hormonal cascade that governs vascular tone,
ﬂuid-electrolyte balance, and blood pressure [64].
4.Adipokines andCardiacFunction
Many studies have shown eﬀects on the heart of various
adipokines. TNF-α has been considered to be a critical
factor in the pathogenesis of cardiac contractile dysfunction
and heart failure. Transgenic mice with overexpression of
TNF-α develop severe dilated cardiomyopathy [11], and
TNF-α directly depresses cardiomyocyte contractility and
induces apoptosis of cardiomyocytes in vitro [65]. TNF-α
has negative inotropic eﬀects on cardiomyocytes in vitro,
and leads to heart failure in mice [66–72]. In addition,
elevated serum TNF-α levels have been associated with the
progression of heart failure in patients [66].
Experimental ﬁndings have shown that adiponectin
has several beneﬁcial eﬀects in the cardiovascular system.
Adiponectin plays an essential role in the maintenance of
heart architecture, as the cytokine may attenuate angiotensin
II-induced cardiac hypertrophy [73] and attenuate car-
diomyocyte contractile dysfunction in db/db diabetic obese
mice via a mechanism possibly related to c-Jun and IRS-1
phosphorylation [74].
Moreover, adiponectin represses atherosclerotic lesions
in a mouse model of atherosclerosis, and adiponectin-
deﬁcient mice exhibit an accelerated vascular remodeling
response to injury [75]. In addition, adiponectin stimulates
nitric oxide production in endothelial cells through AMPK-
dependent and AMPK-independent phosphorylation of
endothelial nitric oxide synthase (eNOS) [76, 77]a n d
hypoadiponectinemia is associated with the progression of
leftventricularhypertrophy(LVH),whichisaccompaniedby
diastolic dysfunction [78].
An association between serum leptin concentrations and
various cardiovascular risks, including myocardial infarction
[79], coronary heart disease [40], stroke [39], chronic heart
failure [80], and left cardiac hypertrophy [81], has been
observed.
Several works suggested that leptin could be an impor-
tant link between obesity and development of cardiovascular
disease [82]. This might be mediated through various eﬀects
of leptin including eﬀect on blood pressure [83], inﬂamma-
tory vascular response [42, 84], and platelet aggregation [85,
86]. High levels of leptin are associated with lower arterial
distensibility [87] and have also been shown by several inves-
tigators to promote angiogenesis, enhance the calciﬁcation
of vascular cells, and potentiate the prothrombotic platelet
aggregation [86, 88] moreover, obese individuals possess
higher plasma levels of prothrombotic factors such as ﬁb-
rinogen, von Willebrand factor, factor VII, and plasminogen
activator inhibitor-1 (PAI-1), which lead to a higher risk of
thrombosisandatherosclerosis.Thelevelsofpro-thrombotic
factors such as ﬁbrinogen, von Willebrand factor, factor VII,
and plasminogen activator inhibitor-1 (PAI-1) are shown to
be directly correlated with leptin levels [89].
Ghrelin is not produced by the adipose tissue; however,
the functions of this gastric peptide are closely related to
those of adipokine regarding metabolic and cardiovascular
function.
Ghrelin has been demonstrated to have cardiovascular
eﬀects, both in animals and humans. Ghrelin protects the
heart from ischemia in rats, and chronic administration of
the peptide improves cardiac contractility in animals with
chronic heart failure [90]. Furthermore, in the heart of
rats subjected to ischemia followed by reperfusion, ghrelin
reduces the infarct size [91], increases cardiac output,
diastolic thickness of the noninfarcted wall, and attenuates
the development of cardiac cachexia in rats with heart failure
[92]. In humans, ghrelin administration reduces cardiac
afterload and increases cardiac output and systemic vascular
resistance, without changing heart rate [93]. Moreover, ghre-
lin administration increases exercise capacity and improves
left ventricular function and muscle wasting in patients with
chronic heart failure [94–96].
5. Adipose TissueInﬂammation
Recent observations from Kamei et al. [97] on transgenic
mice have led to the concept that obesity contributes to IR
and diabetes promoting a condition of chronic, low-grade
inﬂammation of the adipose tissue because of additional
inﬁltration and accumulation of inﬂammatory macrophages
[98–102].Themacrophagecontentofadiposetissueishigher
invisceralobesitycomparedtosubcutaneousobesity,leading
to the concept that visceral fat more than subcutaneous
one plays a central role in the development of IR [103].
Macrophages appear to be recruited from the circulation,
and adipocyte-derived factors might be involved in this
process.
Monocyte chemoattractant protein-1 (MCP-1) is pro-
duced predominantly by macrophages and endothelial cells
and is considered one of the most important potent
chemotactic factors for monocytes. The increase of MCP-1
expression in adipose tissue contributes to the macrophage
inﬁltration and IR associated with obesity.4 Cardiology Research and Practice
The general low-grade chronic inﬂammatory state,
closely related to obesity, may aﬀect insulin action by
suppressing insulin receptor signalling via serine phos-
phorylation of insulin receptor substrates at metabolically
relevant sites [104]. Because favourable metabolic and
hemodynamic actions of insulin share common intracellular
transduction pathways [105], inﬂammation may simultane-
ously contribute to both IR and vascular dysfunction, two
cardinal and interrelated features of the Mets. Moreover,
macrophages become activated and secrete inﬂammatory
cytokines such as TNF-alpha and IL.6 which in turn decrease
insulin action on adipocytes, determine hypoadiponectin,
and increase leptin production [98, 106]. TNF-α indeed
plays a central role in the pathophysiology of IR and
vascular damage in patients with obesity; the deletion of the
TNF-α gene or the TNF receptors has proven eﬀective to
improve insulin action in both genetic and dietary models
of rodent obesity. Overexpression of TNF-α has previously
been reported in obese adipose tissue [62, 107], as well as in
the skeletal muscle of insulin-resistant animals and humans
and exposure to TNF-α acutely inhibits insulin-stimulated
glucose uptake. Additionally, TNF-α-induced vasculopa-
thy is characterized by increased vascular reactive oxygen
species.
WehavepreviouslydemonstratedthatTNF-αneutraliza-
tion with the monoclonal antibody inﬂiximab ameliorates
insulin-stimulated vascular reactivity in Mets [108]. Our
ﬁndings suggest that increased oxidative stress is involved
in mediating the eﬀects of TNF-α on insulin-stimulated
vasodilator capacity. The beneﬁcial action on vascular
reactivity demonstrated in our study proposes a novel
mechanism by which TNF-α activation might be involved,
viaincreased oxidative stress, in the pathophysiology of
vascular dysfunction in patients with obesity-related MetS.
The degree to which any particular adipose-derived
inﬂammatory mediator enters the blood stream and plays
a role in metabolic and cardiovascular disorders has not yet
been established [109].
An emerging area of interest is the role of perivascular
adipose tissue (PVAT)in regulating localvasculartone [110].
The presence of adipose tissue around the heart and the
great vessels has been recently recognized as an independent
cardiovascular risk factor. The perivascular adipose tissue
(PVAT) is the potential source of the mediators leading to
obesity-related vascular damage.
Because of the absence of the fascial boundaries, epicar-
dial adipose tissue may locally interact and aﬀect the coro-
nary arteries and myocardium through paracrine actions of
pro- and anti-inﬂammatory adipokines and other bioactive
molecules [111].
Thus,theepicardialandperivascularadiposetissuecould
mechanically and functionally modulate the function of the
myocardium and vasculature thereby possibly playing a role
in obesity-related atherosclerosis [112].
Several studies demonstrated that epicardial fat pro-
duces a number of bioactive molecules as well as TNF-
alpha, IL-6, IL-1, resistin, free fatty acid, and adiponectin
that could aﬀect cardiovascular morphology and function
[113–117].
Moreover, recent studies have shown that perivascular
adipocytes physiologically exert anticontractile eﬀects which
are both NO dependent and independent.
In particular, adipokines released from fat depots have
local rather than systemic vasoregulatory eﬀects, a mech-
anism deﬁned as vasocrine signaling. In healthy subjects,
PVAT seems to mediate an anticontractile eﬀect in medium-
and small-sized arteries [118, 119].
Adiponectin is the main candidate for this role based
on the ﬁnding that the anticontractile properties of the fat
are abolished entirely with an adiponectin type 1 receptor
blocking fragment [119].
Importantly, this eﬀect of PVAT is lost in patients with
obesity-related metabolic syndrome, and conformational
changes in perivascular fat have been shown to associate
with lots of its anticontractile properties likely due to inﬂam-
matory, vasoconstrictor, and oxidative mechanisms. Recent
studies has demonstrated a positive correlation between epi-
cardial adipose tissues volume and coronary atherosclerosis
using multislice computed tomography [120].
Moreover, Hosogai and colleagues demonstrated that
PVAT of obese mice is hypoxic and that hypoxia stimulated
an inﬂammatory phenotype and a loss of the anticontractile
properties. This eﬀect is mediated by endoplasmic reticulum
stress and posttranscriptional regulation. Because hypoxia
is a prominent feature of adipose tissue in obese individ-
uals and is thought to cause adipocyte dysfunction and
tissue inﬂammation [121], these ﬁndings further support a
prominent role for PVAT-derived inﬂammatory cytokines in
adversely modulating vascular function.
Of note, the obese phenotype could be reproduced by
adding the inﬂammatory cytokines IL-6 or TNF-α to the
PVAT around healthy vessels, which in turn could be blocked
by cytokine antagonists.
In conclusion, these studies suggest that PVAT in obese
individuals predominately exerts inﬂuence that contributes
to vascular disease and may act both locally (paracrine) and
downstream (vasocrine), through outside-to-inside signal-
ing.
6. Renal Effects of Obesity
The most common types of morphological renal lesions
observed in renal biopsies of obese patients are mainly focal
and segmental glomerulosclerosis and glomerulomegaly
[122].The podocyte foot processeﬀacementdescribed in the
ADP knockoutmice probably represents an earlier stage of
kidney involvement. Early changes occurring in the presence
of only mild metabolic abnormalities and mild hyperten-
sion in the absence of diabetes mellitus include increased
glomerular cell proliferation, increased mesangial matrix,
thicker basement membrane, and increased expression of
glomerular transforming growth factor-beta [50].
In a recent study, Lamacchia and colleagues demon-
strated that para- and perirenal fat thickness is an indepen-
dent predictor of kidney dysfunction and increased renal
resistance in patients with type 2 diabetes [123].
The mechanisms of obesity-induced renal injury are not
fully understood and are likely to involve a combination ofCardiology Research and Practice 5
hemodynamic and metabolic abnormalities. Many factors
contribute to the increase in both glomerular ﬁltration rate
(GFR) and rise in renal plasma ﬂow (RPF) observed in
obesepatients.Theincreasedproteinintakedeterminesarise
in GFR [124]. Moreover, IR causes increase in the eﬀerent
arteriolar pressure because the reduction of noradrenaline-
induced eﬀerent arteriolar constriction by insulin action is
blunted. Subsequently, the transcapillary pressure gradient
increases resulting in hyperﬁltration [124]. Augmented
ﬁltration determines microalbuminuria. Moreover, insulin
stimulates the synthesis of IGF-1 and IGF-2, both promoting
glomerular hypertrophy [122, 124]. The rapid and parallel
increases in the prevalence of end-stage renal disease and
obesity in the past two decades suggest that obesity may
be a major risk for kidney disease through other mecha-
nisms than diabetes and hypertension (see Figure 1)[ 125].
Additionally, obesity increases the risk of development of
renal diseases from diﬀe r e n ta e t i o l o g i e s ,s u c ha sp r i m a r y
immunoglobulin A nephritis or unilateral nephrectomy
[126, 127]. Whether weight loss, in the long term, can
slow down the progression of renal damage or reverse it is
unknown at the present time. In the short term, weight loss
usually leads to reduction of the proteinuria. Antiproteinuric
eﬀects of weight loss are also observed in obese patients with
nephropathies due to other causes [126].
7. Mechanismsof Vascular Damage inObesity
Abdominal obesity is well recognized as a major risk factor
forCVD,buttheunderlyingmechanismsofvasculardamage
in obesity remain poorly understood.
One of the most important mechanisms by which
obesity leads to the development of vascular diseases is the
development of IR in skeletal muscle, adipose tissue, and
liver. The adipose tissue excess, particularly visceral fat, is
associated with a continuous production of mediators that
impair insulin action in skeletal muscle, like free fatty acids
(FFAs), and is associated with a decreased production of
adiponectin,amediatorknowntoimproveinsulinsensitivity
[128]. Plasminogen activator inhibitor-1 (PAI-1) is typically
increased in the obesity/IR state and plays an important
role in the genesis of vascular abnormalities [129]. In
addition, obesity and IR are frequently associated with
altered coagulation/ﬁbrinolysis. In combination, all of the
aboveabnormalitiescreateastateofconstantandprogressive
damage to the vascular wall, manifested by a low-grade
progressive inﬂammatory process [130]. Endothelial dys-
function is deﬁned as paradoxical or inadequate endothelial-
mediated vasodilation and is characterized by loss of balance
between vasoconstrictors and vasodilators, increased oxida-
tive stress, and elevated expression of proinﬂammatory and
prothrombotic factors.
Endothelial dysfunction is a fundamental initial step in
the development and progression of atherosclerosis and has
been considered an important event in the development of
microvascular complications [130].
Adipose tissue can produce a signiﬁcant amount of
compounds able to aﬀect endothelial function; the ability
of adipokines to directly aﬀect vascular homeostasis may
Visceral fat cells
↓ Adiponectin
↑ Inﬂammatory adipokines
Arterial vessel
Oxidative stress
Kidney
podocyte’s alteration
oxidative stress
Potential interaction between early
kidney disfunction and systemic
Figure 1: Possible dynamic interactions between obesity, CKD,
and CVD. The increase of visceral mass determines both decreased
production of ADN and increased production of inﬂammatory
adipokines which result in increased insulin resistance.
represent an important mechanistic basis of vascular disease
in patients with obesity. Central obesity is associated with
increased levels of free fatty acid (FFA) that induces endothe-
lial dysfunction by eﬀect of insulin-mediated vasodilatation
in humans and by impairment of nitric oxide-independent
mechanism mediated by reduction of potassium-mediated
vasodilatation [131]. The increased levels of FFA from
the more lipolytically active intra-abdominal adipocytes
decreased insulin sensitivity through the intracellular insulin
signaling [132].
Moreover, FFAs are capable of utilizing the innate
immune receptor TLR4 to induce proinﬂammatory cytokine
expression in macrophages and adipocytes. In particular, the
TLR4 signaling appears to be required for a component of
insulin resistance induced by FFAs in adipocytes and in vivo
after lipid infusion and high-fat diets [133].
Moreover, TNF alpha overproduction in obesity medi-
ates the increased endothelial permeability by activating
NADPH oxidase [129] and also inhibits transcriptional, as
well as posttranscriptional, eNOS gene expression an eﬀect
that can account for the endothelial dysfunction.
In obese patients, an increase in reactive oxygen species
has been demonstrated and could be the link between the
low-grade inﬂammation, platelet activation, and nitric oxide
destruction.
In IR and obesity, the dyslipidaemia is characterized by
ad i ﬀerent composition and distribution of LDL choles-
terol, resulting in an increased concentration of the more
atherogenic small dense LDL. Small dense LDL particles can
move through endothelial fenestrations, entering the suben-
dothelial space where inﬂammation and transformation into
plaque can occur [134]. Moreover, the ox-LDL is mostly
taken up by macrophage scavenger receptors, rather than the
normalLDLreceptorpathway,thusinducingatherosclerosis.6 Cardiology Research and Practice
8.VascularDysfunctioninInsulin
Resistance andMetabolic Syndrome
Hyperinsulinemia and IR are established metabolic features
ofobesity.Vasodilatoractionsofinsulintostimulateproduc-
tion of nitric oxide (NO) from vascular endothelium lead to
increased blood ﬂow that further enhances glucose uptake
in skeletal muscle [135, 136]. Insulin binding to its cognate
receptor activates two major branches of insulin signal
transduction network. Metabolic actions of insulin tend
to be mediated by phosphatidylinositol 3-kinase- (PI3K-)
dependent signaling pathways, whereas the nonmetabolic
insulin signalling pathways (MAPK-dependent insulin sig-
naling pathways) typically regulate growth, mitogenesis, and
diﬀerentiation [137, 138] and also regulate the secretion of
the vasoconstrictor endothelin-1 (ET-1) from endothelium.
The PI3K-dependent metabolic actions of insulin
directly promote glucose uptake in skeletal muscle by
stimulatingtranslocationofinsulinresponsiveglucosetrans-
porters (GLUT4). At the same time, PI3K-dependent vascu-
lar actions of insulin to increase blood ﬂow and capillary
recruitment substantially contribute to promoting glucose
disposal under healthy conditions [3].
ET-1, a potent vasoconstrictor synthesized and secreted
byvascularendothelium,playsanimportantroleinendothe-
lial dysfunction.
In humans, insulin-stimulated ET-1 production may
inﬂuence skeletal muscle glucose disposal, and ET-1 infusion
induces peripheral insulin resistance. NO, however, is known
to inhibit ET-1 production and action [139]. Consequently,
under healthy conditions, the eﬀects of insulin-stimulated
ET-1onthemetabolic actionsofinsulinarelikelytobeoﬀset
by insulin-stimulated production of NO [140].
IR is characterized by selective impairment in PI3K-
dependent signalling in both metabolic and vascular insulin
target tissues, and the diminished sensitivity to the actions of
insulin in vascular endothelium contributes importantly to
the clinical phenotype of this condition [3].
In insulin-resistant states, the insulin-mediated ET-1
secretion is augmented, and blockade of ET-1 receptors
signiﬁcantly improves insulin sensitivity and peripheral
g l u c o s eu p t a k ei nt h ec o n t e x to fI R[ 141, 142].
Another important mechanism of insulin action is the
increased microvascular perfusion of skeletal muscle leading
to increased muscle blood ﬂow and glucose uptake.
While the majority of previous studies have focused
on the endothelium-dependent eﬀect of insulin, we have
suggested that the blunted vasodilator responsiveness to the
exogenous NO seen in obese patients during hyperinsuline-
mia could be related to the facilitatory action physiologically
exerted by insulin on vasorelaxation within VSMCs. Indeed,
insulin enhances vasodilator responsiveness by reducing
Ca2+ concentration in VSMCs, via activation of the Na+,K +-
ATPase pump [143]. Similarly, in human VSMCs, insulin
inactivates the small GTPase RhoA and its target, Rho-
kinase, thereby leading to decreased phosphorylation of
myosin light chain and subsequent vasodilation [144].
In a recent study, we have demonstrated that insulin
exerts a facilitatory eﬀect on vascular reactivity to a variety of
vasoactive molecules (acetylcholine, sodium nitroprusside,
and verapamil) by the increased delivery of substrates in
skeletal muscle of healthy subjects, but in contrast with the
results obtained in healthy subjects, the responsiveness of
these vasodilators was not enhanced during hyperinsuline-
mia in the group of patients with the metabolic syndrome
due to increased oxidative stress [145].
9. Conclusion
The rapid growth of obesity is contributing to an “epidemic”
in Mets and diabetes and related renal and cardiovascular
complications. Adipose tissue is an endocrine organ which
produces a variety of “adipokines.” Clinical management
should be aimed to reduce risk factors by encouraging
lifestyle modiﬁcations such as diet, aerobic exercise, and
healthy eating as well as pharmacologic intervention to
improve insulin sensitivity, dyslipidemia, and blood pressure
control and protect the kidney from further injury. At
the present time, there are few drugs available to produce
signiﬁcant long-term weight loss. Weight loss of about 10%
can improve insulin sensitivity and lower blood pressure,
reduce serum lipid levels, decrease plasma inﬂammatory
cytokines,andincreasecirculatingAND[97,146].Finally,an
emergingareaofinterestisthepotentialroleofthepodocyte-
speciﬁc drugs. Further research on adipokines action on
renal cells is needed and will lead to novel treatment
strategies aimed to ﬁght the increased incidence of obesity-
related chronic kidney and cardiovascular diseases.
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